OC-14: Effectiveness and safety of 6-months' treatment with different full-dose enoxaparin regimens in patients with cancer-associated venous thromboembolism: a subgroup analysis of the RIETECAT cohort study. Issue 213 (May 2022) - Monreal, M.; Bertoletti, L.; López-Núñez, J.J.; Tiberio, G.; Soler, S.; Gómez-Cuervo, C.; Fidalgo, Á.; Mellado, M.; López-Miguel, P.; Díaz-Peromingo, J.A.